Biotechnology Value Fund L P's Form 4 filing
Merus N.V. (MRUS) · filed Oct 8, 2021
- Accession no.
- 0001193805-21-001440
- Filed
- Oct 8, 2021, 9:24 PM ET
- Trade date
- Oct 7-8, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $31.2M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | Other: See Explanation of Responses |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | Other: See Explanation of Responses |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | Other: See Explanation of Responses |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 7, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −530,999 | $27.53 | −$14,618,986.57 | 2,165,675 | Direct | |
| Oct 8, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −80,011 | $27.79 | −$2,223,225.65 | 2,085,664 | Direct | |
| Oct 7, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −384,914 | $27.53 | −$10,597,105.83 | 1,578,732 | Direct | |
| Oct 8, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −58,327 | $27.79 | −$1,620,703.19 | 1,520,405 | Direct | |
| Oct 7, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −69,534 | $27.53 | −$1,914,347.51 | 241,676 | Direct | |
| Oct 8, 2021 | Common Shares, (euro)0.09 nominal value per share | SSaleDisposed | −8,929 | $27.79 | −$248,105.66 | 232,747 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.